UA138856U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes a clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of the gene for methylenetetrahydrofolate reductase (MTHFR C677T), the content of endothelin, folic acid, C-terminal propeptide of collagen type I (SISR), C-reactive protein (SRP), interleukin 6 (L). With a homozygous carrier of 677-TT and levels of endothelin> 10 ng / ml, folic acid <6 ng / ml, SISR <102 ng / ml, PSA> 6 mg / l, IL-6> 10 ng / l, homocysteine> 20 μmol / l predict the development of osteoarthritis.

Description

The proposed useful model for predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. The method is intended and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N.

Okorokov Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to conducting a clinical examination and radiography, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEV C677T), the content of endothelin, folic acid, C - terminal propeptide of type I collagen (SICR), C - reactive protein (CRP) are determined in the patient's blood serum ), interleukin 6 (IL-6), homocysteine and with homozygous carrier 677-TT, the content of endothelin » 10 ng/ml, folic acid « b ng/ml, SISR « 102 ng/ml,

SRP » 6 mg/l, IL-6 » 10 ng/l, homocysteine » 20 μmol/l predict the development of osteoarthritis.

Application of the method.

During hospitalization, the patient is examined, x-rays are taken, and the MTNEV C677T gene polymorphism is determined. The content of endothelin, folic acid,

SISR, SRP, IL-b6, homocysteine. With homozygous carrier 677-TT, levels of endothelin » 10 ng/ml, folic acid « 6 ng/ml, SISR » 102 ng/ml, SRP » 6 mg/l, IL-6 » 10 ng/l, homocysteine » 20 μmol /l predict the development of osteoarthritis.

A specific example of using the method.

Patient Zh., 58 years old, was hospitalized in the clinic due to pain syndrome in the right hip joint. X-rays were examined and carried out. No signs of osteoarthritis were found. Polymorphism of MTNEV C677T gene was determined in blood serum. The content of endothelin, folic acid, SISR, SRP, IL-6, and homocysteine was determined by immunoenzymatic method. Homozygous carrier 677-TT was established. Levels of endothelin - 25 ng/ml, folic acid - 3.2 ng/ml, SICP - 78 ng/ml, SRP - 17 mg/l, IL-b - 22 ng/l, homocysteine - 44 μmol/l. The development of osteoarthritis was diagnosed. After 11 months, X-rays showed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA A method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that in the patient's blood serum, the polymorphism of the methylenetetrahydrofolate reductase gene (MITNEV Sb677T), the content of endothelin, folic acid, C-terminal propeptide of type I collagen (CRP), C-reactive protein (CRP), interleukin 6 (IL-6), homocysteine, and with homozygous carrier 677-111 and endothelin levels of 210 ng/ml, folic acid "6 ng/ml, SISR "102 ng/ml, SRP 26 mg/l, IL-6 210 ng/l, homocysteine 220 μmol/l predict the development of osteoarthritis.